A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model

Shi, Lijuan and Zhang, Zhihua and Hölscher, Christian (2017) A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model. Behavioural Brain Research, 327. pp. 65-74. ISSN 0166-4328

[img]
Preview
PDF (1-s2.0-S0166432817302243-main)
1_s2.0_S0166432817302243_main.pdf - Accepted Version
Available under License Creative Commons Attribution-NonCommercial-NoDerivs.

Download (1MB)
[img]
Preview
PDF (DA4 in STZ rat model)
DA4_in_STZ_rat_model.pdf - Accepted Version
Available under License Creative Commons Attribution-NonCommercial.

Download (1MB)

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, accompanied by memory loss and cognitive impairments, and there is no effective treatment for it at present. Since type 2 diabetes (T2DM) has been identified as a risk factor for AD, the incretins glucagon-like peptide 1 (GLP-1) and glucose dependent insulinotropic polypeptide (GIP), promising antidiabetic agents for the treatment of type 2 diabetes, have been tested in models of neurodegenerative disease including AD and achieved good results. Here we show for the first time the potential neuroprotective effect of a novel dual GLP-1/GIP receptor agonist (DA-JC4) in the icv. streptozotocin (STZ)-induced AD rat model. Treatment with DA-JC4 (10 nmol/kg ip.) once-daily for 14 days after STZ intracerebroventricular (ICV) administration significantly prevented spatial learning deficits in a Y- maze test and Morris water maze tests, and decreased phosphorylated tau levels in the rat cerebral cortex and hippocampus. DA-JC4 also alleviated the chronic inflammation response in the brain (GFAP-positive astrocytes, IBA1-positive microglia). Apoptosis was reduced as shown in the reduced ratio of pro-apoptotic BAX to anti- apoptotic Bcl-2 levels. Importantly, insulin signaling was re-sensitized as evidenced by a reduction of phospho-IRS1Ser1101 levels and phospho-AktSer473 up-regulation. In conclusion, the novel dual agonist DA-JC4 shows promise as a novel treatment for sporadic AD, and reactivating insulin signaling pathways may be a key mechanism that prevents disease progression in AD.

Item Type:
Journal Article
Journal or Publication Title:
Behavioural Brain Research
Additional Information:
This is the author’s version of a work that was accepted for publication in Behavioral Brain Research. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Behavioral Brain Research, 327, 2017 DOI: 10.1016/j.bbr.2017.03.032
Uncontrolled Keywords:
/dk/atira/pure/subjectarea/asjc/2800/2802
Subjects:
ID Code:
85715
Deposited By:
Deposited On:
27 Mar 2017 10:34
Refereed?:
Yes
Published?:
Published
Last Modified:
30 Sep 2020 06:49